| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Classified under Biotechnology (Health Care sector), CYCN's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 21, 2024 | Slate Path Capital LP | 10% Owner | Sell | 357,880 | $1.55 | $555,107.67 | -100% | +102.8% | +4.2% | |
| Aug 9, 2023 | McGuire Terrance | Director | Sell | 8 | $3.40 | $27.16 | -100% | -29.2% | -12.7% | |
| Jun 3, 2021 | Slate Path Capital LP | 10% Owner | Buy | 961,538 | $3.12 | $2,999,998.56 | +15.5% | -0.6% | -81.6% | |
| Jun 3, 2021 | McGuire Terrance | Director | Buy | 96,153 | $3.12 | $299,997.36 | -135.1% | -0.6% | -81.6% | |
| Jun 3, 2021 | Hecht Peter M | Chief Executive Officer | Buy | 823,170 | $3.28 | $2,699,997.60 | +67.2% | -0.6% | -81.6% | |
| May 6, 2021 | Hecht Peter M | Chief Executive Officer | Buy | 302,000 | $2.43 | $733,860.00 | +32.7% | +23.7% | -75.9% | |
| May 5, 2021 | Hecht Peter M | Chief Executive Officer | Buy | 698,001 | $2.43 | $1,693,942.53 | +310.9% | +21.2% | -72.2% | |
| Feb 25, 2021 | Gjino Anjeza | Chief Financial Officer | Sell | 1,824 | $4.00 | $7,296.00 | -5.5% | - | - | |
| Feb 25, 2021 | Wright Christopher I | Chief Medical Officer | Sell | 2,637 | $3.99 | $10,521.63 | -5.8% | - | - | |
| Dec 28, 2020 | Currie Mark G53 | President and CSO | Sell | 20,107 | $3.01 | $60,522.07 | -7.4% | - | - |